Document is current

Article History

First Online: 3 February 2020

Compliance with Ethical Standards

:

: Priscila Oliveira de Lima declares that she has no conflict of interest.Shannon Joseph has a patent pending 2015 Methods for Classifying Tumors and Uses Therefore (Simpson F, Joseph S).Benedict Panizza declares that he has no conflict of interest.Fiona Simpson recently completed an investigator-led contract with Merck KgAa on avelumab; has an issued patent 2015 WO2014063206-A1 “classifying epidermal growth factor receptor-positive tumor into subtype, e.g., epidermal growth factor receptor antagonist sensitive subtype, involves analyzing ligand-induced epidermal growth factor receptor internalization status of tumor” (Simpson F, Saunders NA); has an issued patent 2015 WO2014063205-A1 “composition useful in kit for treating tumor, preferably cell surface antigen-positive tumor, e.g., cancerous tumors, comprises antibody that binds to cell surface antigen of tumor and inhibitor of receptor-mediated endocytosis” (Simpson F, Saunders NA); and has a patent pending 2015 Methods for Classifying Tumors and Uses Therefore (Simpson F, Joseph S).

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Free to read: This content has been made available to all.